Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3911 ARTÍCULOS , VIENDO DEL 1366 AL 1380

2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors

Legoabe LJ, Petzer A, Petzer JP.

Drug Des Devel Ther. 2015 Jul 15;9:3635-44. doi: 10.2147/DDDT.S86225. eCollection 2015.

Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders

Cai Y, An SS, Kim S.

Clin Interv Aging. 2015 Jul 14;10:1163-72. doi: 10.2147/CIA.S85808. eCollection 2015.

Imaging Nigrostriatal Dopaminergic Deficit in Holmes Tremor with 18F-PR04.MZ-PET/CT

Juri C, Chana P, Kramer V, Pruzzo R, Amaral H, Riss PJ, Rösch F.

Clin Nucl Med. 2015 Sep;40(9):740-1. doi: 10.1097/RLU.0000000000000868.

Therapeutic potential of PACAP for neurodegenerative diseases

Yang R, Jiang X, Ji R, Meng L, Liu F, Chen X, Xin Y.

Cell Mol Biol Lett. 2015 Jun;20(2):265-78. doi: 10.1515/cmble-2015-0008.

Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis

Jethwa KD, Onalaja OA.

BJPsych Open. 2015 Jul 24;1(1):27-33. doi: 10.1192/bjpo.bp.115.000927. eCollection 2015 Jun.

Chaperone-mediated autophagy and neurodegeneration: connections, mechanisms, and therapeutic implications

Liu X, Huang S, Wang X, Tang B, Li W, Mao Z.

Neurosci Bull. 2015 Aug;31(4):407-15. doi: 10.1007/s12264-015-1542-8. Epub 2015 Jul 23.

Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease

Cummings J, Zhong K.

Clin Pharmacol Ther. 2015 Nov;98(5):483-5. doi: 10.1002/cpt.190. Epub 2015 Aug 31.

Influence of propofol on oxidative-antioxidative system parameters in peripheral organs of rats with Parkinson disease

Romuk E, Szczurek W, Nowak P, Kwiecień I, Stolecka D, Birkner E.

Postepy Hig Med Dosw (Online). 2015 Jun 12;69:661-7. doi: 10.5604/17322693.1156935.

Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease

Gan-Or Z, Dion PA, Rouleau GA.

Autophagy. 2015;11(9):1443-57. doi: 10.1080/15548627.2015.1067364.

Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients

Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS.

Mov Disord. 2015 Oct;30(12):1648-56. doi: 10.1002/mds.26290. Epub 2015 Jul 24.

A historical overview of protein kinases and their targeted small molecule inhibitors

Roskoski R Jr.

Pharmacol Res. 2015 Oct;100:1-23. doi: 10.1016/j.phrs.2015.07.010. Epub 2015 Jul 21.

Disease-modifying strategies for Parkinson's disease

Kalia LV, Kalia SK, Lang AE.

Mov Disord. 2015 Sep 15;30(11):1442-50. doi: 10.1002/mds.26354. Epub 2015 Jul 24.

Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease

Pourcher E, Huot P.

Mov Disord Clin Pract. 2015 Jul 25;2(4):331-340. doi: 10.1002/mdc3.12187. eCollection 2015 Dec.

Invasive Treatment Strategies in a Patient with PARK 15-Associated Parkinsonism

Spielberger S, Seppi K, Wolf E, Eisner W, Poewe W.

Mov Disord Clin Pract. 2015 Jul 25;2(4):434-435. doi: 10.1002/mdc3.12151. eCollection 2015 Dec.

Olfaction in Homozygous and Heterozygous SYNJ1 Arg258Gln Mutation Carriers

Picillo M, De Rosa A, Pellecchia MT, Criscuolo C, Amboni M, Erro R, Bonifati V, De Michele G, Barone P.

Mov Disord Clin Pract. 2015 Jul 25;2(4):413-416. doi: 10.1002/mdc3.12183. eCollection 2015 Dec.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias